Introducing Novavax’s Protein-Based COVID-19 Vaccine
The Food and Drug Administration (FDA) recently authorized Novavax’s updated protein-based COVID-19 vaccine for emergency use in individuals ages 12 and up. This development opens up a new option for those looking for an alternative to the mRNA vaccines offered by Pfizer and Moderna.
Novavax’s vaccine targets the highly contagious omicron subvariant JN.1, which has been circulating widely in the U.S. The company’s shot provides protection against descendants of JN.1 that are currently dominant in the country, including KP.2.3, KP.3, KP.3.1.1, and LB.1.
CEO John Jacobs has stated that Novavax’s updated vaccine is effective against JN.1 lineage viruses and offers robust cross-reactivity. The company anticipates that its vaccine will be widely available in thousands of locations across the U.S., including retail and independent pharmacies and regional grocers.
This news has caused shares of Novavax to rise more than 8%. The FDA’s decision to authorize Novavax’s vaccine comes shortly after approving new mRNA shots from Pfizer and Moderna targeting another offshoot of JN.1 called KP.2.
For individuals hesitant about mRNA vaccines, Novavax’s protein-based technology provides a familiar approach to fighting the virus. This method has been used for decades in routine vaccinations against diseases like hepatitis B and shingles. With only around 22.5% of U.S. adults receiving the latest round of shots last fall, the availability of Novavax’s vaccine offers an additional option for those seeking protection against COVID-19.
Stay tuned for more updates on the availability and distribution of Novavax’s vaccine as we continue to monitor the latest developments in the fight against COVID-19. Stay informed and stay safe with Extreme Investor Network.